Proteomics International Managing Director Dr Richard Lipscombe said he was delighted to welcome Dr Elliott and Mr Gardiner to the Board.
“Robyn and Neville bring a fantastic combination of skills to further strengthen our team. At this pivotal stage in our company’s development their wealth of knowledge will be invaluable. With operational insights from Australia’s most successful life science company and tier one capital markets experience we look forward to them accelerating the next phase of Proteomics International’s growth.”
Mr Gardiner and Dr Elliott said that they were excited to join the PIQ Board at a time when the company was poised for substantial growth, and with enormous opportunities across its deepening pipeline of iinnovative tools for the improved treatment of disease.